Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Suresh K. Durgam sold 7,344 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, March 13th. The stock was sold at an average price of $45.04, for a total transaction of $330,773.76. Following the completion of the sale, the executive vice president now directly owns 23,104 shares of the company’s stock, valued at approximately $1,040,604.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Intra-Cellular Therapies Stock Performance
ITCI opened at $45.31 on Wednesday. Intra-Cellular Therapies, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $66.00. The firm’s fifty day moving average is $48.16 and its 200 day moving average is $49.20. The stock has a market cap of $4.32 billion, a price-to-earnings ratio of -16.66 and a beta of 1.13.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last released its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.17. Intra-Cellular Therapies had a negative net margin of 102.37% and a negative return on equity of 35.88%. The company had revenue of $87.87 million for the quarter, compared to analysts’ expectations of $86.97 million. During the same quarter in the previous year, the company earned ($1.05) EPS. Intra-Cellular Therapies’s revenue for the quarter was up 242.3% on a year-over-year basis. On average, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -2.42 earnings per share for the current year.
Analysts Set New Price Targets
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Intra-Cellular Therapies by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 8,116,020 shares of the biopharmaceutical company’s stock worth $377,638,000 after purchasing an additional 35,822 shares in the last quarter. BlackRock Inc. lifted its stake in Intra-Cellular Therapies by 0.8% in the 3rd quarter. BlackRock Inc. now owns 7,102,050 shares of the biopharmaceutical company’s stock worth $330,459,000 after purchasing an additional 53,693 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Intra-Cellular Therapies in the 1st quarter worth $248,502,000. Alliancebernstein L.P. lifted its stake in Intra-Cellular Therapies by 4.2% in the 3rd quarter. Alliancebernstein L.P. now owns 2,200,408 shares of the biopharmaceutical company’s stock worth $102,385,000 after purchasing an additional 87,821 shares in the last quarter. Finally, Lord Abbett & CO. LLC lifted its stake in Intra-Cellular Therapies by 9.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 2,018,686 shares of the biopharmaceutical company’s stock worth $93,929,000 after purchasing an additional 167,737 shares in the last quarter. Hedge funds and other institutional investors own 86.95% of the company’s stock.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.
- Get a free copy of the StockNews.com research report on Intra-Cellular Therapies (ITCI)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.